Ontology highlight
ABSTRACT:
SUBMITTER: Lickliter JD
PROVIDER: S-EPMC7090185 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
Lickliter Jason D JD Gan Hui K HK Voskoboynik Mark M Arulananda Surein S Gao Bo B Nagrial Adnan A Grimison Peter P Harrison Michelle M Zou Jianjun J Zhang Lianshan L Luo Stacey S Lahn Michael M Kallender Howard H Mannucci Andrea A Somma Catello C Woods Katherine K Behren Andreas A Fernandez-Penas Pablo P Millward Michael M Meniawy Tarek T
Drug design, development and therapy 20200318
<h4>Purpose</h4>Camrelizumab inhibits PD-1 in non-clinical models and showed typical non-clinical pharmacokinetic (PK) and safety profiles for an IgG4 monoclonal antibody. We report results from the First-in-Human Phase 1 trial of camrelizumab in Australian population.<h4>Methods</h4>Camrelizumab was administered to patients with advanced solid tumors who had failed standard therapies. In the dose-escalation phase (n=23), camrelizumab was administered intravenously at 1 mg/kg, 3 mg/kg, 6 mg/kg, ...[more]